ScholarIQanswers from OpenAlex & ORCID
Yuri Rukazenkov
ResearcherPublications, citations & collaboration network
Yuri Rukazenkov is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Yuri Rukazenkov have?
ScholarIQindexed works
Yuri Rukazenkov has 91 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Yuri Rukazenkov have?
ScholarIQcitation count
Yuri Rukazenkov has 17,567 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Yuri Rukazenkov?
ScholarIQh-index
Yuri Rukazenkov has an h-index of 30 in OpenAlex.
What is the i10-index of Yuri Rukazenkov?
ScholarIQi10-index
Yuri Rukazenkov has an i10-index of 46 in OpenAlex.
What is the OpenAlex record for Yuri Rukazenkov?
ScholarIQopenalex
The OpenAlex for Yuri Rukazenkov is on the source record.
What are the most-cited papers on Yuri Rukazenkov?
ScholarIQmost cited works
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Byoung Chul Cho, Ying Cheng, Eun Kyung Cho, Pei Jye Voon, David Planchard, Wu‐Chou Su, Jhanelle E. Gray, Siow Ming Lee, Rachel Hodge, Marcelo Marotti, Yuri Rukazenkov, Suresh S. Ramalingam
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E. Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong, Riyaz Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng‐Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean‐Charles Soria
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong, Swan-Swan Leong, Virote Sriuranpong, Tsu-Yi Chao, Kazuhiko Nakagawa, Da-Tong Chu, Nagahiro Saijo, Emma Duffield, Yuri Rukazenkov, Georgina Speake, Haiyi Jiang, Alison Armour, Ka‐Fai To, James Chih‐Hsin Yang, Tony Mok
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
David Planchard, Pasi A. Jänne, Ying Cheng, James Chih‐Hsin Yang, Noriko Yanagitani, Sang‐We Kim, Shunichi Sugawara, Yan Yu, Yun Fan, Sarayut Lucien Geater, К. К. Лактионов, Chee Khoon Lee, Natalia Valdiviezo, Samreen Ahmed, Jean-Marc Maurel, Igor Andrašina, Jonathan W. Goldman, Dana Ghiorghiu, Yuri Rukazenkov, Alex Todd, Kunihiko Kobayashi